Exploring the Therapeutic Potential of GLP-1 Receptor Agonists in Polycystic Ovary Syndrome

Miis Akel[1], Aya Ziq[1], Paul Kaldas[1], Abdul Rahman Omari[1], Jad Hamden[2], Allen Silanee MD[3]

Background

Polycystic Ovary Syndrome (PCOS) is an endocrine disorder affecting 4-20% of women worldwide, characterized by disrupted menstrual cycles, elevated androgen levels, and polycystic ovaries. This condition leads to metabolic dysfunction, increased cardiovascular risk, and fertility challenges, reducing the quality of life for affected individuals. PCOS development involves genetic, hormonal, and environmental factors, with insulin resistance and chronic inflammation playing significant roles.

Traditional treatments include hormonal contraceptives, insulin-sensitizing medications like metformin, and lifestyle changes. However, their effectiveness and patient adherence vary. This has spurred interest in alternative treatments, such as glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (Ozempic), initially used for Type 2 diabetes. These medications aid in weight loss, improve insulin sensitivity, and have anti-inflammatory properties, making them promising for PCOS management.

Despite their benefits, GLP-1 receptor agonists come with risks, such as contraindications in patients with a history of medullary thyroid cancer or pancreatitis and potential adverse reactions. This review explores the use of GLP-1 receptor agonists in PCOS treatment, evaluating their strengths and weaknesses to enhance care and develop tailored treatment strategies for individuals with PCOS.

Objective

This review aims to understand the impact of GLP-1 receptor agonists on PCOS outcomes and symptoms. Additionally, it seeks to raise awareness of GLP-1 receptor agonist use in PCOS to improve the quality of care through tailored treatment strategies.

Methods



Results



Reference	Study Design	Participants	Interventions	Outcomes	Recommendations	Limitations
Elkind-Hirsch et al. (2021)	Randomized Controlled Trial	Obese women with PCOS (N=36)	Exenatide (Bydureon), Dapagliflozin, Phentermine/Topiramate	Significant weight and body fat reduction, improved glucose metabolism, insulin sensitivity, testosterone, FAI, blood pressure	Dual therapy for clinical and metabolic benefits	Short duration (24 weeks), single-blinded, specific demographic (18-45 years)
Jensterle et al. (2015)	Prospective Randomized Open-label Trial	Obese women with PCOS (N=45)	Metformin, Liraglutide (Victoza), Roflumilast	Significant weight loss with liraglutide, improved glucose metabolism, insulin sensitivity, reduced testosterone levels, increased menstrual frequencies	Short-term therapy with liraglutide or roflumilast	Small sample size, short observation period, introduction of lifestyle interventions
Jensterle et al. (2017)	Randomized Controlled Trial	Obese women with PCOS (N=30)	Liraglutide (Victoza), Liraglutide + Metformin	Significant weight loss, improved metabolic parameters, glucose homeostasis	Combination therapy of liraglutide and metformin	Short duration (12 weeks), small sample size
Jensterle et al. (2014)	Randomized Controlled Trial	Obese women with PCOS (N=32)	Liraglutide (Victoza), Metformin	Significant reductions in BMI, body weight, waist circumference, whole-body fat mass, liraglutide more effective in a subgroup with severe obesity	Liraglutide for patients with severe metabolic derangements	Small sample size, short duration (12 weeks)
Jensterle et al. (2023)	Single-center, randomized, single-blind, placebo-controlled trial	Women with PCOS (N=20)	Semaglutide (Ozempic)	Significantly delayed gastric emptying, increased retention of gastric contents	Semaglutide for managing weight and metabolic control	Small sample size, short duration
Jensterle et al. (2014)	Randomized Controlled Trial	Overweight/obese women with PCOS and prediabetes (N=183)	Exenatide (Bydureon), Metformin, or both	Combination therapy achieved higher remission rates of prediabetes, improved glucose metabolism	Combination therapy for effective management of prediabetes in PCOS patients	Short duration (24 weeks), single-center, specific population (Chinese women)
Jensterle et al. (2015)	Randomized Controlled Trial	Obese women with PCOS (N=36)	Liraglutide (Victoza)	Significant weight loss, improved metabolic parameters, eating behavior, emotional eating	Liraglutide for managing eating behavior and promoting weight loss	Short duration, small sample size
Kahal et al. (2015)	Randomized Controlled Trial	Young obese women with PCOS (N=77)	Liraglutide (Victoza)	Significant weight reduction, improved cardiovascular risk markers, inflammatory markers, endothelial function	Liraglutide for reducing cardiovascular risk in obese women with PCOS	Short duration (6 months), small sample size
Nylander et al. (2017)	Double-blind, placebo-controlled, randomized clinical trial	Women with PCOS (N=72)	Liraglutide (Victoza), Placebo	Significant weight loss, improved bleeding regulation, reduced androgen levels, ovarian volume	Liraglutide for improving ovarian function and bleeding patterns in PCOS	Short duration (26 weeks), small sample size
Li et al. (2017)	Randomized Controlled Trial	Overweight/obese women with PCOS (N=136)	Exenatide (Bydureon), Metformin	Significant weight loss, fat loss with Exenatide, improved reproductive and metabolic functions	Exenatide for managing weight and metabolic parameters in overweight/obese women with PCOS	Short-term study, need for longer-term evaluation
Jensterle et al. (2015)	Randomized, open-label, parallel-group controlled trial	Overweight/obese PCOS patients with prediabetes (N=183)	Exenatide (Bydureon), Metformin, Combination	Combination therapy showed highest remission rates of prediabetes, significant suppression of postprandial insulin secretion	Combination therapy for improving glucose metabolism in PCOS with prediabetes	Short duration (24 weeks), single-center study, specific population (Chinese women)

Discussion

Metabolic Benefits:

Studies consistently reported significant reductions in body weight, BMI, and waist circumference with GLP-1 receptor agonists, indicating decreased abdominal adiposity and correlated improvements in PCOS symptoms related to insulin resistance, infertility, and psychological well-being.

The most substantial improvements in fasting insulin sensitivity were observed with GLP-1 receptor agonists or their combinations, particularly exenatide-metformin regimens. While monotherapy showed no significant changes in endocrine parameters, combinations with metformin reduced total testosterone levels, potentially alleviating symptoms like hirsutism and acne. Specific findings included liraglutide's lack of impact on total testosterone and semaglutide's influence on androstenedione, free testosterone, and sex hormone-binding globulin (SHBG).

Menstrual Cycle and Fertility:

Treatment with GLP-1 receptor agonists, including exenatide, was associated with increased menstrual frequency and improved cycle regularity. The weight loss and hormonal regulation induced by these agonists may contribute to enhanced fertility in PCOS patients.

Additionally, studies reported decreased inflammatory markers, supporting the role of GLP-1 receptor agonists in hormonal regulation, ovulation, and successful conception. A study by Liu et al. demonstrated higher natural pregnancy rates in patients treated with exenatide compared to those receiving metformin.

Limitations and Future Implications:

Overall, GLP-1 receptor agonists show promise in managing the metabolic and reproductive challenges of PCOS, though our study has limitations, including variability in PCOS presentations and the need for more large-scale randomized controlled trials.

Further research is necessary to explore the long-term effects and safety of GLP-1 receptor agonists and compare different therapies for personalized treatment strategies.

.

Conclusion

This study highlights the potential of GLP-1 receptor agonists in managing PCOS by promoting weight loss, improving insulin sensitivity, reducing inflammation, and regulating menstrual cycles. While promising, further research is needed to understand their long-term effects. A personalized approach will be crucial for optimizing treatment, making GLP-1 receptor agonists a valuable option for enhancing PCOS care.

References